Bioengineering/NanomedicineIn vitro Effect of bethanechol (cas 111244-96-3) and Suberyldicholine on Regions of Guinea Pig Esophagus
-
Add time:08/30/2019 Source:sciencedirect.com
BackgroundTissue engineering and regenerative medicine is envisaged as the future option for esophageal replacement; however, engineering of a functional esophagus is impeded by the limited understanding of the anatomical complexity of this dynamic muscular organ. The aim of this study was to characterize the function of native esophageal tissue and determine differences in functional response to stimulation between anatomical sites.
We also recommend Trading Suppliers and Manufacturers of bethanechol (cas 111244-96-3). Pls Click Website Link as below: cas 111244-96-3 suppliers
Prev:Phase III randomised trialDouble blind randomized prospective trial of bethanechol (cas 111244-96-3) in the prevention of radiation-induced salivary gland dysfunction in head and neck cancer patients
Next:Liver, Pancreas and Biliary Tractbethanechol (cas 111244-96-3) provocation testing does not predict symptom relief after cholecystectomy for acalculous biliary pain) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- In vitro effects of bethanechol (cas 111244-96-3) on smooth muscle preparations from abomasal fundus, corpus, and antrum of dairy cows09/04/2019
- Short communicationAn adult case of cerebral malakoplakia successfully cured by treatment with antibiotics, bethanechol (cas 111244-96-3) and ascorbic acid09/03/2019
- bethanechol (cas 111244-96-3)-induced responses in mudpuppy parasympathetic neurons09/02/2019
- INVESTIGATIVE UROLOGYELECTROMOTIVE ADMINISTRATION OF INTRAVESICAL bethanechol (cas 111244-96-3) AND THE CLINICAL IMPACT ON ACONTRACTILE DETRUSOR MANAGEMENT:: INTRODUCTION OF A NEW TEST09/01/2019
- Liver, Pancreas and Biliary Tractbethanechol (cas 111244-96-3) provocation testing does not predict symptom relief after cholecystectomy for acalculous biliary pain08/31/2019
- Phase III randomised trialDouble blind randomized prospective trial of bethanechol (cas 111244-96-3) in the prevention of radiation-induced salivary gland dysfunction in head and neck cancer patients08/29/2019


